ArticleClinical case reports2025
Pleuropulmonary Blastoma in a Pediatric Patient: A Case Report and Review of Current Diagnostic and Treatment Strategies.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pleuropulmonary Blastoma in a Pediatric Patient: A Case Report and Review of Current Diagnostic and Treatment Strategies.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleuropulmonary blastoma (PPB) is a rare, highly aggressive pulmonary tumor that typically presents in the pediatric population. The overall prognosis of PPB is poor, although type I PPB can regress spontaneously. In this case report, the authors present a 3.5-year-old boy histopathologically diagnosed with PPB type III, who underwent three courses of the ifosfamide, vincristine, actinomycin D, and doxorubicin (IVADO) chemotherapy regimen after surgical resection. Although the initial post-chemotherapy evaluations showed no residual or metastatic tumor, based on PET-CT scan findings, it relapsed 4 months after the last chemotherapy course. Finally, the patient expired due to disease progression. In addition to the case presentation, the authors provide an overview of PPB and discuss how this case illustrates key diagnostic and management challenges in advanced PPB type III.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.